Ready to climb
Well this baby is ready to go higher, it is making higher lows and seems very well consolidated. There is an FDA report for an expedite development of its major depressive disorder (MDD) and postpartum depression (PPD) treatment, SAGE-217. This would be the final phase of trials before receiving the right to file a New Drug Application with the FDA and potentially market the drug early next year.
SAGE is focused on the development of products for the treatment of life-threatening central nervous system disorders.
As of now, there are two products under development based on the NMDA (N-methyl-D-aspartate) receptor program: SAGE-718 and SAGE-904.
It looks like a good to go for the rest of the year, be ready to get out at +30% - +40%
SAGE is focused on the development of products for the treatment of life-threatening central nervous system disorders.
As of now, there are two products under development based on the NMDA (N-methyl-D-aspartate) receptor program: SAGE-718 and SAGE-904.
It looks like a good to go for the rest of the year, be ready to get out at +30% - +40%
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。